- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04766931
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
A Two-part, Phase I/II, Multi-center, Double-Blind, Randomized, Vehicle-controlled Study of the Safety and Efficacy of FB2001 in Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Infection
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Secaucus, New Jersey, United States, 07094
- Frontage Clinical Services, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects are required to meet ALL of the following criteria for enrollment into the Part 1 of the study:
- Male or female adults who are between 18 and 60 years old inclusive;
- Weigh at least 45kg, with a BMI of 19 to 30 kg/m2 inclusive;
- No serious underlying disease which would adversely affect the study conduct and data interpretation per the investigator;
Female subjects should have negative results in serum pregnancy test at screening and negative urine pregnancy test at admission:
- Subjects of reproductive age and their partners agree to take 2 forms of effective contraceptive measures. Note: Using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), implantable device (implantable rod or intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]
Surgically sterile, with documentation, for at least 3 months prior to screening by one of the following means:
Bilateral tubal ligation, Bilateral salpingectomy (with or without oophorectomy), Surgical hysterectomy, Bilateral oophorectomy (with or without hysterectomy), Postmenopausal, defined as the following: Last menstrual period greater than 12 months prior to screening
- Postmenopausal status confirmed by serum follicle stimulating hormone (FSH) and estradiol levels at screening
- Agree to refrain from alcohol during the study;
- Subjects should have normal (or abnormal but not clinically significant) laboratory results per the PI's judgement including the complete blood count, biochemistry, coagulation indices and urinalysis;
- Subjects should have a normal (or abnormal but not clinically significant) ECG and chest X-ray at screening;
- Subjects should be willing to cooperate and able to participate in this study, comply with all protocol requirements, and sign an informed consent;
- Male subjects with female partners of childbearing potential must agree to use condoms for the duration of the study and until 12 weeks after completion of dosing with the study drug and must refrain from donating sperm for this same period;
- Current non-smokers and those who have not smoked within the last 6 months. This includes the use of cigarettes, e-cigarettes, and nicotine replacement products.
Exclusion Criteria:
Subjects are required to meet NONE of the following criteria for enrollment into the Part 1 of the study:
- HIV antibody positive;
- HbsAg positive;
- HCV antibody positive;
- History of tuberculosis or lung disease as reported by subject;
- As reported by the subject has severe cardiovascular disease, neurological disease, hematological disease, infectious disease, mental disorder, liver disease, gastrointestinal disease, lung disease, endocrine disease,immune disease or kidney disease, or has a history of the above diseases, or other symptoms known to interfere with the absorption, distribution, metabolism, or excretion of the medicine, or other conditions that the investigator believes will increase the risk of the subject and might interfere with the study conduct and results interpretation
- Female subjects who are pregnant, lactating or have pregnancy plans in the 3 months after their study completion;
- Subjects who participated in any other clinical study within 30 days prior to screening;
- Subjects with known allergic reactions to the study drug or its excipients;
Use of any medication, including prescription or over the counter, vitamins, herbal and/or mineral supplements, dietary supplements (and/or grape fruit juice) within 14 days prior to the first treatment or during the trial, which in the opinion of the investigator may influence the trial results or the safety of the subjects:
- Poor venous access or issues with needle sticks, e.g., syncope
- Donated or lost >500 mL of blood in the previous 3 months
- A history of prescription drug abuse, illicit drug use within 9 months prior to screening
- A positive screen for alcohol or drugs of abuse at screening or admission
- Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A1 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A2 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A3 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A4 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A5 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A6 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A7 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: B1 FB2001 or Placebo
Once daily for 5 days
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: B2 FB2001 or Placebo
Once daily for 5 days
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: A8 FB2001 or Placebo
single dose
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
Experimental: B3 FB2001 or Placebo
Twice daily for 5 days
|
Subjects will be administered with FB2001 by intravenous (IV) infusion
Other Names:
Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Maximum Tolerable Dose (MTD)
Time Frame: 0~5 days
|
Determination of the Maximum Tolerable Dose (MTD) of FB2001 based on the occurrence of Dose Limiting Toxicities (DLTs).
|
0~5 days
|
Number of participants with treatment-related adverse events as assessed by CTCAE V4.0
Time Frame: 0~28 days
|
Evaluation of the safety and tolerability of FB2001 after a single and multiple dose administrations in healthy volunteers.
|
0~28 days
|
Pharmacokinetic parameters(Cmax)
Time Frame: 0~5 days
|
Estimate of steady state Cmax for multiple dose administration of FB2001.
|
0~5 days
|
Pharmacokinetic parameters(AUC0-τ)
Time Frame: 0~5 days
|
Estimate of steady state AUC0-τ for multiple dose administration of FB2001.
|
0~5 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cheng Yao, Frontier Biotechnologies Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FB2001-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on FB2001
-
Frontier Biotechnologies Inc.RecruitingEvaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19Mild to Moderate COVID-19China
-
Frontier Biotechnologies Inc.Recruiting
-
Frontier Biotechnologies Inc.Completed
-
Frontier Biotechnologies Inc.Completed
-
Ruijin HospitalFrontier Biotechnologies Inc.; Shanghai Center for Disease Control and PreventionNot yet recruitingClose Contact Transmission